<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823923</url>
  </required_header>
  <id_info>
    <org_study_id>PROICM 2020-08 IRE</org_study_id>
    <secondary_id>2020-A01533-36</secondary_id>
    <nct_id>NCT04823923</nct_id>
  </id_info>
  <brief_title>Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer</brief_title>
  <acronym>IREKI</acronym>
  <official_title>Study of the Impact of the Stage of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors (ITK) in Patients Treated for Metastatic Kidney Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month&#xD;
      and 3 months from the start of treatment will allow to evaluate the impact of renal failure&#xD;
      on their efficacy and toxicity in patients with metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves patients treated with cabozantinib or pazopanib in their metastatic renal&#xD;
      cancer.&#xD;
&#xD;
      Indeed, the aim of this study is to assess the blood concentration of these two drugs as well&#xD;
      as their tolerance, in relation to their renal function (normal renal function or moderate or&#xD;
      severe renal failure).&#xD;
&#xD;
      Pazopanib and cabozantinib are kinase inhibitors that are indicated for a number of cancer&#xD;
      conditions, including metastatic kidney cancer.&#xD;
&#xD;
      Both of these oral therapies require a daily intake of the drug to ensure its effectiveness.&#xD;
&#xD;
      For this, the patient must have optimal compliance and benefit from regular follow up to&#xD;
      assess clinical and biological tolerance.&#xD;
&#xD;
      Chronic renal failure is a factor that may impact the efficacy and toxicity of pazopanib and&#xD;
      cabozantinib. This may be due either to a elimination default of the drug or to much&#xD;
      elimination if the drug is filtered after dialysis.&#xD;
&#xD;
      As a result, kinase inhibitors could be impacted by chronic renal failure and thus modify the&#xD;
      safety and efficacy of the treatment.&#xD;
&#xD;
      A study-specific blood test will be taken at 1 month and at 3 months during a consultation&#xD;
      (this blood test is in addition to the routine blood test). Its analysis will evaluate the&#xD;
      quantity of medication present in the blood.&#xD;
&#xD;
      The other objective of this study is to evaluate the side effects of the drug taken by the&#xD;
      patient (pazopanib or cabozantinib).&#xD;
&#xD;
      This will alow to propose possible dose adjustments for each of these treatments and thus&#xD;
      improve the management of these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Residual concentration at equilibrium of ITK in the blood</measure>
    <time_frame>at 1 month (+/1 week)</time_frame>
    <description>Assessment in patients treated for metastatic kidney cancer without or with moderate or severe renal impairment if the plasma concentration (residual concentration at equilibrium) of ITK is higher than the target concentration (specific to the ITK molecule : pazopanib : 20 000 ng/mL and cabozantinib : 1000 ng/mL )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of ITK in the blood in patients with Failure renal function</measure>
    <time_frame>at 1 month (+/- 1 week) and 3 months (+/- 1 month)</time_frame>
    <description>Assessment the plasma concentration (residual concentration at equilibrium) of ITK (pazopanib and / or cabozantinib) in patients with moderate renal impairment and / or severe renal impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of ITK in the blood in patients with normal renal function</measure>
    <time_frame>at 1 month (+/- 1 week) and 3 months (+/- 1 month)</time_frame>
    <description>Assessment the plasma concentration (residual concentration at equilibrium) of ITK (pazopanib and / or cabozantinib) in patients with normal renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities related to the intake of ITKs</measure>
    <time_frame>at 1 month (+/- 1 week) and 3 months (+/- 1 month)</time_frame>
    <description>Assessment toxicities induced by the use of ITK targeting Vascular Endothelial Growth Factor-Receptor (VEGF-R) by using the NCI-CTCAE version 5.0 (grade ≥ 2)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Neoplasm</condition>
  <arm_group>
    <arm_group_label>Patients without renal insufficiency under pazopanib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without renal insufficiency under cabozantinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with moderate renal impairment under pazopanib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with moderate renal impairment under cabozantinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with severe or terminal stage renal impairment under pazopanib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with severe or terminal stage renal impairment under cabozantinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling for ITK dosage</intervention_name>
    <description>Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)</description>
    <arm_group_label>Patients with moderate renal impairment under cabozantinib</arm_group_label>
    <arm_group_label>Patients with moderate renal impairment under pazopanib</arm_group_label>
    <arm_group_label>Patients with severe or terminal stage renal impairment under cabozantinib</arm_group_label>
    <arm_group_label>Patients with severe or terminal stage renal impairment under pazopanib</arm_group_label>
    <arm_group_label>Patients without renal insufficiency under cabozantinib</arm_group_label>
    <arm_group_label>Patients without renal insufficiency under pazopanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient followed for metastatic clear cell renal cell carcinoma.&#xD;
&#xD;
          2. Age ≥18 years old.&#xD;
&#xD;
          3. Performance Status (PS) according to Eastern Cooperative Oncology Group (ECOG) = 0, 1&#xD;
             or 2&#xD;
&#xD;
          4. Patient treated with a VEGF-R inhibitor: pazopanib or cabozantinib, in the 1st, 2nd or&#xD;
             3rd line of treatment for metastatic kidney cancer.&#xD;
&#xD;
          5. If patient doesn't have renal failure -&gt; group 1, or if patient has chronic renal&#xD;
             failure according to the moderate stage Chronic Kidney Disease - Epidemiology&#xD;
             (CKD-EPI) formula (Clr &lt;60 ml / min, stage 3) -&gt; group 2, or if patient have chronic&#xD;
             renal failure according to the CKD-EPI formula of severe or terminal stage (Clr &lt;30 ml&#xD;
             / min, stage 4 and stage 5), with or without dialysis -&gt; group 3.&#xD;
&#xD;
          6. Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests and other study procedures.&#xD;
&#xD;
          7. Patient having given informed, written and express consent.&#xD;
&#xD;
          8. Affiliation to the French Social Security System.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Indication other than clear cell renal cell carcinoma for these same ITKs&#xD;
&#xD;
          2. Pregnant or breast-feeding subjects&#xD;
&#xD;
          3. Patient whose regular follow-up is impossible for psychological, family, social or&#xD;
             geographic reasons,&#xD;
&#xD;
          4. Patient under guardianship, curatorship or safeguard of justice&#xD;
&#xD;
          5. Participation in another clinical study with a research product during the last 30&#xD;
             days before inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny LEENHARDT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cancer de Montpellier (ICM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre BLEUSE</last_name>
    <phone>04 67 61 31 02</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>APHM Hôpital LA TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent DEVILLE, Dr</last_name>
      <phone>04 91 38 57 08</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-laurent.deville@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Hôpital St Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elodie CHARTRON, Dr</last_name>
      <phone>04 67 33 01 37</phone>
      <phone_ext>+33</phone_ext>
      <email>e-chartron@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny LEENHARDT, Dr</last_name>
      <phone>04 67 61 24 77</phone>
      <phone_ext>+33</phone_ext>
      <email>Fanny.Leenhardt@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes, Institut de Cancérologie du Gard</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadine HOUEDE, Pr</last_name>
      <phone>04 66 68 33 01</phone>
      <phone_ext>+33</phone_ext>
      <email>nadine.houede@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine CHEVREAU, Dr</last_name>
      <phone>05 31 15 51 03</phone>
      <phone_ext>+33</phone_ext>
      <email>chevreau.christine@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. Review.</citation>
    <PMID>19733976</PMID>
  </reference>
  <reference>
    <citation>Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Sci Pharm. 2017 Feb 27;85(1). pii: E8. doi: 10.3390/scipharm85010008.</citation>
    <PMID>28264440</PMID>
  </reference>
  <reference>
    <citation>Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group. Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients. Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. Epub 2016 Jul 28.</citation>
    <PMID>27470967</PMID>
  </reference>
  <reference>
    <citation>Lacy S, Yang B, Nielsen J, Miles D, Nguyen L, Hutmacher M. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. Cancer Chemother Pharmacol. 2018 Jun;81(6):1071-1082. doi: 10.1007/s00280-018-3581-0. Epub 2018 Apr 23.</citation>
    <PMID>29687244</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic kidney cancer</keyword>
  <keyword>pazopanib</keyword>
  <keyword>cabozantinib</keyword>
  <keyword>renal failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

